CytomX Therapeutics, Inc. CTMX initiated enrolment by dosing first patient in a Phase 1 dose-escalation study of CX-904 for patients with advanced solid tumors.
CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment.
Amy C. Peterson, M.D., president and chief operating officer, commented : "Our conditionally activated TCB platform is designed to localize both target binding and T-cell activation selectively to the tumor microenvironment, minimizing extra-tumoral activation of T cells and potentially widening the therapeutic window for solid tumor-directed TCBs. This study underscores our commitment to destroying cancer differently and bolsters our leadership in the field of conditional activation in oncology.”
Price Check: Shares of CytomX Therapeutics are trading high at $1.55 in Thursday’s regular session, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.